Co-reporter:Ahmed M. Galal, Waseem Gul, Desmond Slade, Samir A. Ross, Shixia Feng, Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Mahmoud A. ElSohly
Bioorganic & Medicinal Chemistry 2009 Volume 17(Issue 2) pp:741-751
Publication Date(Web):15 January 2009
DOI:10.1016/j.bmc.2008.11.050
Twelve artemisinin acetal dimers were synthesized and tested for antitumor activity in the National Cancer Institute (NCI) in vitro human tumor 60 cell line assay, producing a mean GI50 concentration between 8.7 (least active) and 0.019 μM (most active). The significant activity of the compounds in this preliminary screen led to additional in vitro antitumor and antiangiogenesis studies. Several active dimers were also evaluated in the in vivo NCI hollow fiber assay followed by a preliminary xenograft study. The title compounds were found to be active against solid tumor-derived cell lines and showed good correlation with other artemisinin-based molecules in the NCI database. The dimers were also evaluated for their antimalarial and antileishmanial activities. The antimalarial activity ranged from 0.3 to 32 nM (IC50), compared to 9.9 nM for artemisinin.Twelve artemisinin acetal dimers were synthesized and tested for anticancer, antiangiogenesis and antiprotozoal activities. Full spectroscopic data are given for the title compounds.